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To investigate the effects ofellagic acid (EA) on the cytotoxicity, B-lymphocytes isolated from CLL patients
and healthy individuals. Flow cytometric assay was used to measure the percentage of apoptosis versus
necrosis, intracellular active oxygen radicals (ROS), mitochondrial membrane potential (MMP) and the
caspase-3 activity and then mitochondria were isolated from both groups B-lymphocytes and parameters
of mitochondrial toxicity was investigated. Based on our results EA decreased the percentage of viable
cells and induced apoptosis. EA increased ROS formation, mitochondria swelling, MMP decrease and
cytochrome c release in mitochondria isolated from CLL BUT NOT healthy B-lymphocytes while pre-
treatment with cyclosporine A and Butylated hydroxyl toluene (BHT) prevented these effects. Our results
suggest that EA can act as an anti cancer candidate by directly and selectively targeting mitochondria
could induce apoptosis through mitochondria pathway with increasing ROS production which ﬁnally
ends in cytochrome c release, caspase 3 activation and apoptosis in cancerous B-lymphocytes isolated
from CLL patients.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer is a leading cause of death in developed and developing
countries [1,2]. Searching for new anticancer agents from plant
and other sources is a promising approach which may lead to the
discovery of many novel anti-cancer agents [3,4]. Chronic lym-
phocytic leukemia (CLL) is a neoplasm characterized by clonal
proliferation and accumulation of immature lymphocytes in the
blood, lymph nodes, spleen and bone marrow. CLL is the most
common leukemia in Western countries, and it accounts for ap-
proximately one-third of all leukemias in the United States and
other counties [5]. The median age for diagnosis of CLL is 65 years,
and the disorder is higher in men than women [6]. However, de-
spite the initial effectiveness of used anti-cancer drugs in patients
with low-grade disease, resistant cells ultimately emerge, leaving
no effective treatment options available. It is possible that drug-
resistant CLL cells possess intrinsic defect(s) in their ability toB.V. This is an open access article u
eheshti University of Medical
8218820 9620.
. Pourahmad).undergo apoptosis. Apoptosis is a physiological cell suicide pro-
gram that is essential for the regulation of development, the
maintenance of homeostasis and the prevention of tumorigenesis
[7]. Evading the apoptotic program is one of the hallmarks of
cancer and represents an important mechanism in clinical re-
sistance to therapies [8,9]. This is particularly true for chronic
lymphocytic leukemia (CLL), a currently incurable condition that is
clearly characterized by impaired apoptosis [10]. The development
of therapeutic strategies that target apoptosis in CLL is therefore a
very important issue [11]. CLL is typically sensitive to a variety of
cytotoxic drugs, but the disease is considered incurable [12].
Treatment is generally recommended to control symptoms and
reduce bulk of disease but without substantially improving sur-
vival [13]. New targets such as mitochondria has facilitated the
development of new drugs with a view to improving clinical
outcomes for this neoplasm [14]. It is now clear that mitochondria
are central to cell death, cell differentiation, innate immune sys-
tem, hypoxia sensing, metabolism of calcium and amino acids, iron
sulfur center and heme biosynthesis [15]. Disruption to these
processes contributes to several pathologies, such as cancer,
making mitochondria an important therapeutic target [16]. Innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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phenotype, especially resistance to apoptosis, limitless pro-
liferative potential and metabolic reprogramming [17]. It has been
suggested that the most efﬁcient mitochondrially targeted thera-
pies would affect mitochondrial processes that participate in the
establishment of several of this features [18]. Consistently, altera-
tion in mitochondrial dynamics (i.e. ﬁssion and fusion) and da-
mage to mitochondrial macromolecules, can induce cell death by
apoptosis or autophagy [19]. Besides, mitochondria control the
programmed cell death via several mechanisms that can be acti-
vated by disruption of mitochondrial bioenergetics, alteration of
cellular redox balance and release or activation of pro-apoptotic
factors [20,21]. So mitochondria are currently regarded as central
organelles in mediating intrinsic death signals and might provide a
novel target for new chemotherapeutics [18].
Ellagic acid is a naturally occurring phenolic compound that is
contained in ellagitannins in grapes, nuts, strawberries, black
currents, raspberries, green tea, pomegranates, and the stem and
bark of Eucalyptus globulus and as well as royal jelly and honey
[22]. EA exerts potent preventive and therapeutic effects against
several types of cancers, including colon cancer, breast cancer,
prostate cancer, skin cancer, esophageal cancer, and osteogenic
sarcoma. The anti-carcinogenic properties of EA have drawn in-
creasing attention globally [23].
In our study for ﬁrst time we evaluated anti-cancer effect of EA
on B-lymphocytes obtained from CLL patients. We isolated
B-lymphocytes from CLL patients and healthy donors and then
isolated mitochondria from both groups. Parameters such as cell
viability, apoptosis versus necrosis %, caspase 3 activity, ROS for-
mation and collapse of MMP in intact B-lymphocytes and succi-
nate dehydrogenases activity, ROS formation, collapse of MMP,
mitochondrial swelling and release of cytochrome C in isolated
mitochondria was tested.2. Materials and methods
2.1. Patients
Ten newly diagnosed, untreated CLL patients were enrolled into
the study. Diagnosis of CLL was made on the basis of clinical ex-
amination, morphological and immunological criteria. Peripheral
blood (PB) samples were obtained from the patients after in-
formed consent. Age-matched controls were obtained from 10
healthy donors. This study was approved by the Shahid Beheshti
University of Medical Sciences research ethics committee
and all the patients and healthy donors signed an informed con-
sent form.2.2. B-lymphocyte isolation
Blood samples were obtained from the CLL patient and healthy
donors during a routine diagnosis at Shohadaye Tajrish Hospital. B
lymphocytes were isolated immediately using Ficoll gradient
centrifugation. After 1 h of incubation at 37 °C in 5% CO2, adhesive
mononuclear cells were removed. Those non-adherent lympho-
cytes were thoroughly washed with the Hank's solution. T lym-
phocytes were removed using anti-CD3 dynabeads. The puriﬁca-
tion of B lymphocytes was assessed by ﬂow cytometry with anti-
CD19 antibodies with FACS. This cell preparation contained about
95% CD19 (B lymphocyte antigen) positive cells. It was added
stromal cell-derived factor-1 to rescue B-lymphocytes from
apoptosis [24].2.3. Cell viability assay
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) staining as described by
Mosmann [25]. The MTT assay is based on the reduction of the
tetrazolium salt, MTT, by viable cells. The dehydrogenases using
NADH or NADPH as co-enzyme can convert the yellow form of the
MTT salt to insoluble, purple formazan crystals [26]. Formazan
solution is read spectrophotometrically after the crystals are dis-
solved in organic solvent (DMSO). B-lymphocytes
(1104 cells/well) were incubated in 96-well plates in the pre-
sence or absence of EA for 48 h in a ﬁnal volume of 50 ml. At the
end of the treatment, 20 ml of MTT (5 mg/ml in PBS) was added to
each well and incubated for an additional 4 h at 37 °C. The purple–
blue MTT formazan precipitate was dissolved in 100 ml of DMSO
and the absorbance was measured at 570 nm on ELISA reader.
Each concentration was tested in three different experiments run
in three replicates for each sample.
2.4. Measurement of apoptosis versus necrosis
The healthy and CLL B-lymphocytes exposed to EA in duration
24 h and at times 6,12 and 24 h, apoptosis versus necrosis % were
measured. In the early stages of apoptosis phosphatidylserine (PS)
is translocated from the inner side of the plasma membrane to the
outer layer. Annexin V, a calcium dependent phospholipid-binding
protein with a high afﬁnity for PS, can, therefore, be used as a
sensitive probe for the exposure of PS on the cell membrane and
hence as a marker of apoptosis. Brieﬂy, double-staining for FITC-
Annexin V binding and for cellular DNA using propidium iodide
(PI) was performed in duplicate. After washing twice times in PBS,
the B-lymphocytes were resuspended in binding buffer. FITC-An-
nexin V was added to a ﬁnal concentration of 10 mM and the cells
were incubated in the dark for 10 min. The cells were then washed
again in PBS, centrifuged at 300 g and resuspended in binding
buffer. Prior to ﬂow cytometric analysis 10 mM PI in binding buffer
was added to each sample. The ﬂuorescence signals of annexin V
and PI were measured by ﬂow cytometry on the FL1 and FL3
channels with gating for CD19þ B-lymphocytes based on CD19
and side scattering, respectively. Only annexin V-positive (þ) and
PI-negative () cells were deﬁned as apoptotic [27].
2.5. Determination of caspase-3 activity
Caspase-3 activity was determined in cell lysate of lymphocytes
from different treatments using “Sigma's caspase-3 assay kit
(CASP-3-C)”. In brief, this colorimetric assay is based on the hy-
drolysis of substrate peptide, Ac-DEVD-pNA, through caspase-3.
The released moiety (p-nitroaniline) has a high absorbance at
405 nm. The concentration of the p-nitroaniline (μM) released
from the substrate is calculated from the absorbance values at
405 nm or from a calibration curve prepared with deﬁned p-ni-
troaniline solutions [28].
2.6. Determination ROS in intact B-lymphocytes
CLL and healthy B-lymphocytes (1x106 cells) were treated with
both vehicle (solvent of EA) and EA for 6, 12 and 24 h. After
treatment, B-lymphocytes were washed with PBS. H2DCFDA
(10 mM) was used to measure intracellular reactive oxygen species
as previously described [29,30]. This agent diffuses into cells and is
sequestered intracellularly by de-esteriﬁcation. Subsequent reac-
tion with peroxides generates ﬂuorescent 5-chloromethyl-2′, 7′-
dichloroﬂuorescein (DCF). Cells were read on the FL1 channel of a
Cyﬂow Space-Partec. Mean of ﬂuorescence intensities were
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B-lymphocytes.
2.7. Determination of MMP in intact B-lymphocytes
MMP was determined in B-lymphocytes with both vehicle and
EA at 6,12 and 24 h by ﬂow cytometry using a lipophilic cationic
ΔΨm dependent ﬂuorescent dye rhodamine 123, which was
analyzed in ﬂuorescence detection channel 1 (FL-1). B-lympho-
cytes with intact mitochondria excite an intense green ﬂuores-
cence due to the formation of the dye aggregates, whereas the
monomer dye ﬂuoresce green in cells with a disrupted mi-
tochondrial membrane [31]. All aliquots were incubated at room
temperature for 20 min in the dark with 2 μL of the dye diluted in
PBS at a concentration of 2.5 μg/mL and were analyzed im-
mediately with ﬂow cytometry. Data, from at least 10,000 events
per sample, were recorded and processed using Cyﬂow Space-Partec.
2.8. B-lymphocytes lysis and isolation of mitochondria
B-lymphocytes were lysed and isolated mitochondria from CLL
and healthy B-lymphocytes. Mitochondria were isolated from the
B-lymphocytes by mechanical lysis and differential centrifugation.
Brieﬂy, B-lymphocytes were washed with cold PBS at 4 °C and
centrifuged at 450 g. The pellet was resuspended in cold isola-
tion buffer (75 mmol/L sucrose, 20 mmol/L HEPES, 225 mmol/L
mannitol, 0.5 mmol/L EDTA, pH 7.2), and the cells were disrupted
by homogenization. Nonlysed B-lymphocytes and nuclei were
spun down by centrifugation at 750 g for 20 min. The super-
natant was further spun at 10,000 g for 10 min twice. The pellet,
designated as the mitochondrial fraction, was suspended in assay
buffer (140 mmol/L KCL, 10 mmol/L NaCl, 2 mmol/L MgCl2,
0.5 mmol/L KH2PO4, 20 mmol/L HEPES, 0.5 mmol/L EGTA; ad-
justed to pH 7.2 with KOH). The isolation of mitochondria was
determined by measurement of succinate dehydrogenase. The
assay buffer was supplemented with 1 mg/mL rotenone and
10 mmol/L succinate immediately before use [24].
2.9. Succinate dehydrogenases activity assay using MTT test
The activity of mitochondrial complex II (succinate dehy-
drogenases) was assayed by measuring the reduction of MTT (3-
[4,5–dimethylthiazol–2–yl]-2,5-diphenyltetrazoliumbromide).
Brieﬂy, 100 mL of mitochondrial suspensions (1 mg protein/mL)
was incubated with different concentrations of EA (0, 5, 10, 20, 50
and 100 ml) at 37 °C for 1 h; then, 25 ml of 0.4% of MTT was added
to the medium and incubated at 37 °C for 30 min. The product of
formazan crystals was dissolved in 100 ml DMSO and the absor-
bance at 570 nm was measured with an ELISA reader (Tecan,
Rainbow hermo, Austria) [32].
2.10. Determination of mitochondrial swelling on isolated
mitochondria
Puriﬁed mitochondria were isolated as described above. Mi-
tochondria suspensions (at 100 mg protein per well) were in-
cubated in 96-well plates at 25 °C in swelling buffer (140 mmol/ L
KCl, 10 mmol/L NaCl, 2 mmol/L MgCl2, 0.5 mmol/L KH2PO4,
20 mmol/L HEPES, 0.5 mmol/L EGTA; adjusted to pH 7.2 with KOH)
supplemented with 1 mg/mL rotenone and 10 mmol/L succinate.
Various concentration of EA were added after 10 min of pre-
incubation. The MPT pore inhibitor such as cyclosporine A and
inducer MPT pore such as Caþ2 were added upon initiation of the
preincubation period. Mitochondrial swelling was measured
spectrophotometrically in duration 1 h. This method equates mi-
tochondrial membrane permeability transition with high-amplitude swelling of the mitochondria. Mitochondrial swelling
results in a decrease in absorbance monitored at 540 nm [24].
2.11. Determination of ROS formation on isolated mitochondria
The mitochondrial ROS measurement was performed using the
ﬂuorescent probe DCFH-DA. Brieﬂy, puriﬁed mitochondria were
isolated as described above and were placed in respiration buffer
(0.32 mM sucrose, 10 mM Tris, 20 mM Mops, 50 μM EGTA, 0.5 mM
MgCl2, 0.1 mM KH2PO4 and 5 mM sodium succinate). Following
this step, DCFH-DA was added (ﬁnal concentration, 10 μM) and
then added various concentration ellagic acid, in 1.5-mL eppendorf
tubes (at 1000 mg protein per ml) at 37 °C for an hour. Then, the
ﬂuorescence intensity of DCF was measured using Shimadzu RF-
5000U ﬂuorescence spectrophotometer at an excitation wave-
length of 488 nm and emission wavelength of 527 nm .
Most of the researchers like us use DCFH-DA to measure in-
tracellular generation of H2O2 and other oxidants or monitor redox
signaling changes in cells in response to intra- or extracellular
activation with oxidative stimulus. However, based on some pre-
viously published works the intracellular redox chemistry of DCFH
is complex and there are several limitations associated with the
DCF assay for intracellular H2O2 measurement. One of these lim-
itations which is relevant speciﬁcally for our assays include cyto-
chrome c, a heme protein that is released from mitochondria to
the cytosol during apoptosis, is capable of oxidizing DCFH directly
or indirectly via a peroxidase-type mechanism, forming DCF . The
increase in DCF ﬂuorescence that occurs during apoptosis of cells
loaded with DCFH-DA has frequently been associated with en-
hanced oxidant production. It is necessary to keep these limita-
tions in mind for proper interpretation of data obtained with the
DCFH-DA probe. Even if differences in DCF ﬂuorescence are
documented under control and experimental conditions, one
should consider the various limitations for proper interpretation of
the results [30,33].
2.12. Determination of MMP on isolated mitochondria
Mitochondrial uptake of the cationic ﬂuorescent dye, rhoda-
mine 123, has been used for the estimation of mitochondrial
membrane potential. The mitochondrial fractions
(1000 mg protein/ml) were incubated with 10 mM of rhodamine
123 in MMP assay buffer (220 mM sucrose, 68 mM D-mannitol,
10 mM KCl, 5 mM KH2PO4, 2 mM MgCl2, 50 μM EGTA, 5 mM so-
dium succinate, 10 mM HEPES, and 2 μM Rotenone) and then ad-
ded various concentration EA in 1.5-mL eppendorf tubes (at
1000 mg protein per ml) at 37 °C for an hour. The ﬂuorescence was
monitored using Shimadzu RF-5000U ﬂuorescence spectro-
photometer at the excitation and emission wavelength of 490 nm
and 535 nm, respectively [32].
2.13. Determination of cytochrome c release from isolated
mitochondria
Mitochondria obtained CLL and healthy B-lymphocytes were
incubated in 1.5-mL eppendorf tubes at 37 °C for various periods.
Inhibitor of MPT pore, cyclosporine A at the ﬁnal concentration
5 mmol/l and anti-oxidant BHT also at the ﬁnal concentration
5 mmol/l were added 15 min before the addition of ellagic acid.
Following the incubation, tubes were centrifuged at 10,000 g.
The supernatant contained the cytochrome c released from the
mitochondria (cytosolic fraction), and the pellet consisted of the
mitochondrial fraction. The concentration of cytochrome c was
determined through using the Quantikine Human Cytochrome c
Immunoassay kit provided by R and D Systems, Inc. (Minneapolis,
Minn). Brieﬂy, a monoclonal antibody speciﬁc for human
A. Salimi et al. / Redox Biology 6 (2015) 461–471464cytochrome c was pre-coated onto the microplate. 100 mL of con-
jugate (containing monoclonal antibody speciﬁc for cytochrome c
conjugated to horseradish peroxidase) and 50 mL of control and
test group were added to each well of the microplate. One mi-
crogram of protein from each supernatant fraction was added to
the sample wells. All of the standards, controls and test were ad-
ded to two wells of the microplate. After 2 h of incubation, the
substrate solution (100 mL) was added to each well and incubated
for 30 min. After 100 mL of the stop solution was added to each
well; the optical density of each well was determined through the
aforementioned microplate spectrophotometer set to 450 nm [34].
2.14. Statistical analysis
Results are presented as mean7SD. Assays were performed in
triplicate and the mean was used for statistical analysis. Statistical
signiﬁcance was determined using the one-way ANOVA test, fol-
lowed by the post-hoc Tukey test when appropriate. Statistical
signiﬁcance was set at po0.05. And the parameters of mi-
tochondrial dysfunction were analyzed by two way ANOVA and
Bonferonie posttest. In all graph were expressed as mean7SEM
and po0.05 was considered statistically signiﬁcant. The ﬂow cy-
tometric data was analyzed by Flow Max.3. Results
3.1. Cellular assay
3.1.1. Viability assay
For determination of anti-cancer effect of EA we used MTT as-
say. First we measured the probable cytotoxicity of EA on healthy
B-lymphocytes. Our results on healthy B-lymphocytes showed that
EA wascytotoxic at the highest concentration (200 mM), we
therefore did not use this concentration when we decided to
measure cytotoxicity of EA on CLL B-lymphocytes. Our results with
MTT assayshowed that even at the lowest concentration (5 mM) EA
has toxic effecttoward healthy B-lymphocytes. As shown in graph
B, EA at concentrations of 20, 50 and 100 mM, signiﬁcantly
(po0.001) reduced cell viability down to 59, 38 and 17 % re-
spectively (Fig. 1, graph B), while no toxicitywas recordedat theseFig. 1. Cell viability, B-lymphocytes from CLL and healthy donors, at 1104 cells/well, we
for 48 h. The absorbance representing the viability of B-lymphocytes was determined by
po0.001, n¼5.concentrations on healthy B-lymphocytes (Fig. 1, graph A).
3.1.2. Measurement apoptosis and necrosis
The apoptosis was further quantiﬁed by the externalization of
PS, assessed by annexin V-PI double staining at 6,12 and 24 h
following the exposure with ellagic acid. The percentage of an-
nexin Vþ/PI cells (CD19-gated) increased to 6.73 , 11.35 and 28.16
in CLL B-lymphocytes at 6,12 and 24 h after exposure with 25 mM
ellagic acid, respectively, were signiﬁcantly higher than those of
untreated cancerous control B-lymphocytes (all po0.01) (Fig. 2E–
H). While for healthy B-lymphocytes, EA (25 mM) treatment did
not induce early apoptosis (Fig. 2A–D). Based on these data, EA
appeared to have selective signiﬁcant apoptotic activity toward
CLL B-lymphocytes. Besides, we tested the pre treating effect of
BHT and Cs.A on EA induced apoptosis in CLL B-lymphocytes
within 24 h, Our ﬁndings showed that both compounds sig-
niﬁcantly decreased apoptosis% in EA treated cancerous B-lym-
phocytes (Fig. 2I and J). These results again conﬁrms the role of a
ROS mediated mitochondrial pathway in EA induced apoptosis.
3.1.3. Caspase 3 assay
Caspase-3 is activated in the cell under apoptosis signaling
through both extrinsic (death ligand) and intrinsic (mitochondrial)
pathways. As shown in Fig. 3, EA signiﬁcantly increased the ac-
tivity of apoptosis ﬁnal mediator, caspae-3 in CLL B-lymphocytes.
Increased caspase-3 activity was not shown in healthy B-lym-
phocytes. To ﬁgure out the upstream mechanism involved in EA
induced caspase-3 activation we examined the pretreating effect
of Z-IETD a caspase 8 inhibitor and cyclosporine A (Cs.A), an MPT
pore sealing agent and Butylated hydroxytoluene (BHT), a ROS
scavenger on EA treated CLL B-lymphocytes. Our results showed
that only Cs.A and BHT but not Z-IETD prevented EA induced
caspase 3 activation (po0.001) suggesting that EA activates a
ROS-mediated mitochondrial intrinsic pathway in cancerous
B-lymphocytes which could end in apoptosis.
3.1.4. Determination ROS in intact B-lymphocytes
In our study, EA treatment caused a signiﬁcant increase in in-
tracellular ROS levels in CLL B-lymphocytes (Fig. 4B) BUT NOT in
healthy B-lymphocytes (Fig. 4A). In CLL B-lymphocytes, EA in-
duced increase in intracellular ROS, which was not induced in
healthy B-lymphocytes.re seeded on 96-well plates. EA at 20, 50 and 100 mM concentrations was incubated
the ELISA reader at 570 nm. Data presented as mean7SD. The signiﬁcant level was
Fig. 2. EA induced apoptosis in CLL B-lymphocytes. Freshly isolated and puriﬁed CLL B-lymphocytes were treated with either EA-free medium containing 0.05% (v/v) DMSO
(unexposed control) or 25 mM EA for 6, 12 and 24 h. Early apoptosis was measured by the annexin V assay using ﬂow cytometry at 6, 12 and 24 h after incubation in both
groups. As shown in this ﬁgure, pretreatment with BHT and Cs.A signiﬁcantly inhibited apoptosis in the CLL mitochondria (graph J, graph I). The summarized apoptotic data
was demonstrated at graph K. Results are expressed as means7SD, n¼5, *po0.01 vs. respective control.
A. Salimi et al. / Redox Biology 6 (2015) 461–471 4653.1.5. Determination MMP in intact B-lymphocytes
To search for the indication of mechanisms involved in apop-
tosis, we examined the effects of EA on ΔΨm. The treatment with
EA (25 mM for 24 h) had higher percentage of low ΔΨm in CLL
B-lymphocytes in comparison to the healthy B-lymphocytes
(Fig. 5).The change of ΔΨm in CLL B-lymphocytes has been shown
with arrow.3.2. Mitochondria assay
3.2.1. Succinate dehydrogenase activity
Evaluations of EA for potential activity on mitochondria ob-
tained from both CLL and healthy B-lymphocytes were carried out
by studying the inhibitory effects of the compound on succinate
dehydrogenase activity using the MTT assay. EA (10, 50 mM)
strongly inhibited succinate dehydrogenase activity in only CLL
Fig. 3. CLL and healthy B-lymphocytes (106 cells/mL) were incubated in RPMI 1640
medium in conventional condition (37 °C and 5% CO2-air) following the addition of
EA to both groups. Caspase-3 activity was determined by Sigma-Aldrich kit. The kit
determines produced pNA that is released from the interaction of caspase-3 and
AC-DEVD-pNA (peptide substrate). As shown in ﬁgure, EA signiﬁcantly increased
the activity of caspae-3 in CLL B-lymphocytes BUT NOT in healthy B-lymphocytes.
However only Cs.A (5 mM) and BHT (5 mM) but not Z-IETD (10 mM) prevented EA
induced caspase 3 activation. Values are expressed as mean7SD of three separate
experiments (n¼5).***:Signiﬁcant difference in comparison with healthy control
(po0.001).
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healthy B-lymphocytes the inhibitory effect was shown only at the
highestconcentrations 100 and 200 mM (Fig. 6, graph A).
3.2.2. ROS formation assay
ROS plays a role during cell apoptosis. We examined whether
the level of ROS in CLL and healthy mitochondria were affected by
EA with DCFH-DA staining. As shown by Fig. 7 graph B, treatment
with EA at 5, 10 and 20 mM for 1 h,signiﬁcantly induced ROS
generation (po0.05) in CLL mitochondria. These results suggested
that EA induced ROS generation might underlie its effect on pro-
moting CLL cell apoptosis. However as shown at Fig. 7 graph A,
treatment with EA at above concentrations did not induce ROS
generation in healthy mitochondria.
3.2.3. MMP assay in isolated mitochondria
To search for the identiﬁcation of mechanisms involved in
apoptosis, we examined the effects of EA on membrane perme-
ability of mitochondria (ΔΨm) in isolated mitochondria from both
groups. Treatment with different concentrations of EA (5, 10 and
20 mM for 1 h) induced signiﬁcant decrease in ΔΨm only in mi-
tochondria obtained from CLL patient lymphocytes in comparison
to the their untreated control (Fig. 8, graph B). Treatment with EA
(5, 10 and 20 mM for 1 h) did not induce ΔΨm collapse in mi-
tochondria obtained from normal lymphocytes in comparison to
their untreated control (Fig. 8, graph A). Furthermore, 5 mM cy-
closporine A (an MPT blocker) strongly inhibited the decline of
ΔΨm induced by 10 μM of EA in CLL B-lymphocyte mitochondria
(po0.05). An MPT inducer, CaCl2 (50 mM) was also used as a po-
sitive control in ΔΨm assay (Fig. 8).3.2.4. Mitochondrial swelling in isolated mitochondria
Induction of mitochondrial swelling in isolated lymphocyte
mitochondria was monitored by following 540 nm absorbance
(A540) decrease. EA addition (5, 10 and 20 mM) resulted in an
extensive mitochondrial swelling in CLL mitochondria obtained
from B lymphocytes of CLL patients (Fig. 9, graph B). EA addition to
healthy mitochondria (5, 10 and 20 mM) not resulted mitochon-
drial swelling (Fig. 9, graph A). Furthermore, 5 mM cyclosporine A
(an MPT blocker) strongly inhibited the decline of swelling in
isolated B-lymphocytes mitochondria exposed to 10 μM of EA
(po0.05). An MPT inducer, CaCl2 (50 mM) was also used as a po-
sitive control in MMP assay (Fig. 9).
3.2.5. Cytochrome c release
Our results showed that the EA signiﬁcantly caused mi-
tochondrial swelling and collapse of the mitochondrial membrane
potential. These events could result in mitochondrial permeability
transition and release of cytochrome c from mitochondria into the
cytosolic fraction. As shown in Fig. 10, EA (10 mM) induced sig-
niﬁcant (po0.05) release of cytochrome c in CLL mitochondria
isolated from CLL patients but not healthy mitochondria. Sig-
niﬁcantly, the pretreatment of EA-treated mitochondria with the
MPT inhibitor of cyclosporine A (Cs.A) and butylated hydroxyl
toluene (BHT), an antioxidant, inhibited cytochrome c release as
compared with EA-treated group (10 mM) (po0.05), indicating the
role of oxidative stress and MPT pore opening in cytochrome c
release.4. Discussion
Chronic lymphocytic leukemia (CLL) is the most common form
of leukemia in adults in Western countries [35]. Despite advances
in the treatment of chronic leukemias, CLL continues to be an in-
curable disease with median survival varying from 18 months to
12 years depending on severity [36]. Fludarabine has now been
shown to be the most effective agent in the treatment of the
disease, more effective than the previous standard therapy with
chlorambucil. However, the toxicity of ﬂudarabine has led to
controversy over whether the drug should be used as ﬁrst-line
treatment or only after chlorambucil proved unsuccessful [37]. CLL
is commonly considered as an instance for a malignancy of failed
apoptosis. Cell division must occur, presumably in ‘proliferation
centers’ in tissue microenvironments, accounting for the inexor-
able rise in white blood cell counts in some patients and evidenced
by the shortening of telomeres. However, lack of apoptosis is
considered a major component of the dysregulation of normal
B-cell homeostasis in all subsets of this malignancy [38]. Evasion
of apoptosis is a hallmark of CLL, Therefore there are callings for
new strategies to induce apoptosis in this malignancy [10]. Natural
polyphenols, the most abundant antioxidants in human diet, have
many potential beneﬁts in human health [39]. The relationship
between natural polyphenols, apoptosis and cancer was identiﬁed
by studies on the ability of these compounds to act as cancer
chemo-preventive and/or chemotherapeutic agents [40]. Our re-
sult showed that EA as a natural polyphenol is selectively toxic on
B-lymphocytes obtained from CLL patients (Fig. 1). The manage-
ment of cancer through non selective drug therapies often results
in deleterious effects on the normal healthy human cells which
can result in other adverse reactions on different parts of the body.
Our results also showed that EA has no toxicity on healthy
B-lymphocytes at concentrations used (Fig. 1).
Defected apoptosis signaling represents a major causative fac-
tor in the development and progression of CLL. The ability of CLL
B-lymphocytes to evade engagement of apoptosis can play a sig-
niﬁcant role in their resistance to conventional therapeutic
Fig. 4. Effects of EA on CLL and healthy B lymphocytes. EA-induced ROS generation in CLL but not in healthy B-lymphocytes (A and B). Changes mean of ﬂuorescence
intensity in ROS generation in CLL and healthy B-lymphocytes treated with EA 25 mM for 0–24 h summarized in graph D. Values (mean7S.E.) are from three independent
experiments (D). *po0.05, **po0.01 for difference in ROS generation between healthy and CLL in time interval (D).
A. Salimi et al. / Redox Biology 6 (2015) 461–471 467regimens [10]. We proved that EA selectively induced apoptosis in
CLL but not healthy normal B-lymphocytes (Figs. 2 and 3). Ac-
cording to accepted models, apoptotic cell death can be resulted
from activation of two different but interrelated molecular cas-
cades. An extrinsic pathway transduces the extracellular stimulus,
protein death ligands, through plasmatic membrane [41]. Besides,
an intrinsic pathway controls and monitors the intracellular en-
vironment, the mitochondria, which evaluate the molecularsignals leading to death or survival. Pro apoptotic signals such as
oxidative stress, damage in DNA, and alterations in mitochondrial
membrane trigger apoptosis activation [42].
Findings obtained in this study proved that EA selectively rises
intracellular ROS formation in CLL B-lymphocytes (Fig. 4). The
intrinsic pathway of cell death is especially susceptible to ROS.
Previously, it has been shown that exogenous addition of H2O2 has
an inhibitory effect on Naþ/Hþ exchanger activity resulting in
Fig. 5. The effect of EA on ΔΨm of healthy and CLL B-lymphocytes (A and B). Freshly isolated puriﬁed B-lymphocytes were incubated with 25 mM EA for 24 h. ΔΨm was
measured following rohodamine 123 staining with ﬂow cytometry. The presented data revealed that exposure to EA caused a signiﬁcant decrease in ΔΨm in CLL B-lym-
phocytes compared with those suspended in the EA-free medium with 0.05% (v/v) DMSO (untreated CLL control).
Fig. 6. Succinate dehydrogenase activity. The effect of EA on succinate dehydrogenase activity in both healthy and CLL mitochondria obtained from human lymphocytes were
evaluated by MTT assay following 1 h of treatment. Values are mean7SD of three determinations (graph A and B).
A. Salimi et al. / Redox Biology 6 (2015) 461–471468cytosolic acidiﬁcation, which creates a conducive environment for
apoptosis [43]. The inner mitochondrial protein, ANT, is also a
target of ROS modulation by virtue of its redox-sensitive cysteines,
providing an additional mechanism by which drug-induced ROS
production may activate mitochondrial apoptosis [44] Besides the
mitochondrion is a main source of reactive oxygen species (ROS)
[45]. Our ﬁndings also showed that CLL but not healthy B-lym-
phocytes treated with EA experience collapse of mitochondria
membrane potential (MMP) (Fig. 5). This conﬁrmed that probably
EA selectively targets mitochondria only in CLL B-lymphocytes.
Our results on isolated mitochondria also conﬁrmed that EA se-
lectively inhibited succinate dehydrogenase only in CLL but nothealthy mitochondria (Fig. 6). ROS formation signiﬁcantly also
increased only in CLL but not healthy mitochondria (Fig. 7). In fact,
many anti-tumor agents have been reported to act as pro-oxidant
agents for instance inhibitors of mitochondrial respiratory chain,
chemicals resemble ubiquinone and inhibitors of mitochondrial
antioxidant systems which all can eventually disturb the mi-
tochondrial respiratory chain and lead to further increase in mi-
tochondrial oxidative stress. Therefore mitochondria may appear
as an important target for these compounds [46].
MMP is a universal feature of cell death and is often considered
as the “point of no return” in the cascade of events leading to
apoptosis [47]. Shortly after the discovery that MMP is frequently
Fig. 7. The effect of EA on ROS formation in both healthy and CLL mitochondria. Freshly isolated puriﬁed mitochondria were obtained from both healthy and CLL human
donors incubated with EA for 1 h. ROS was measured by DCFH staining with spectroﬂuorimetric method. The ﬂuorescence intensity of DCF was enhanced by EA in
comparison to control of each group during 1 h of incubation. n¼5. *The minimum signiﬁcant level was po0.05.
A. Salimi et al. / Redox Biology 6 (2015) 461–471 469impaired in cancer, mitochondria have become an attractive target
to induce apoptosis and to overcome resistance to chemotherapy
[48]. Currently, more than 20 mitochondrion-targeted compounds
have been reported to induce apoptosis selectively in malignant
cell lines [49]. We showed that EA could selectively induces col-
lapse of MMP, mitochondrial swelling and cytochrome c release in
CLL mitochondria and as well as in intact CLL B-lymphocytes with
almost no effect on healthy B-lymphocytes and their mitochondria
(Figs. 5 and 8–10), suggesting directly targeting of mitochondrialFig. 8. The effect of EA on ΔΨm decreasing. Freshly isolated puriﬁed mitochondria from h
by rhodamine 123 staining with spectroﬂuorescence method. The presented data reve
patients (graph B) BUT NOT in healthy mitochondria obtained from healthy donors (grap
was po0.05.as a possible mechanism for the anticancer effect of phenolic
compound.
One of our determinative ﬁndings was that EA induced cyto-
chrome C release prevented by BHT (a ROS scavenger) and Cs.A (an
inhibitor of MPT pore). Despite the previously mentioned fact that
cytochrome c , by itself can act as a pollutant by oxidizing DCFH
directly or indirectly via a peroxidase-type mechanism, forming
DCF and demonstrating the false ROS formation during apoptosis
of cells loaded with DCFH-DA, this result conﬁrms thatealthy and CLL B-lymphocytes were treated as indicated above. ΔΨm was measured
aled that EA-induced a decrease in ΔΨm in CLL mitochondria obtained from CLL
h A). Data presented as ﬂuorescence intensity. n¼5. *The minimum signiﬁcant level
Fig. 9. Induction of mitochondrial swelling by EA. Addition of EA (5, 10 and 20 mM) induces mitochondrial swelling in CLL BUT NOT in healthy B lymphocyte mitochondria in
a concentration depending manner. Mitochondria were suspended in swelling buffer and incubated for 1 h. The mitochondrial swelling was measured by following ab-
sorbance (λmax¼540 nm) decrease.
Fig. 10. EA (10 mM) on the cytochrome c release in the CLL and healthy mi-
tochondria isolated from both group. As shown in this ﬁgure, pretreatment of with
BHT and Cs.A signiﬁcantly inhibited cytochrome c release in the CLL mitochondria
BUT NOT in healthy mitochondria. The amount of expelled cytochrome c from
mitochondrial fraction into the suspension buffer was determined using human
Cytochrome c ELISA kit as described in above. Values presented as mean7SD
(n¼5). *#Minimal signiﬁcance level po0.05.
A. Salimi et al. / Redox Biology 6 (2015) 461–471470cytochrome c release measured in our study apparently did not
have any interaction with reactive oxygen species (ROS) de-
termined by DCFH-DA.
ROS may promote MPT (mitochondrial permeability transition)
pore by causing oxidation of thiol groups on the adenine nucleo-
tide translocator [50]. Reactive oxygen species (ROS) play a key
role in promoting mitochondrial cytochrome c release and in-
duction of apoptosis. ROS induce dissociation of cytochrome c
from cardiolipin on the inner mitochondrial membrane, andcytochrome c may then be released via mitochondrial perme-
ability transition (MPT)-dependent or MPT-independent mechan-
isms. Stimuli triggering apoptosis through mitochondria pathway,
resulting in the release of cytochrome c from the mitochondrial
intermembrane space (MPT pores) into cytoplasm and activation
of downstream effectors including caspases [51].
Finally our results suggest that EA can act as an anti-cancer
candidate by directly and selectively targeting mitochondria could
induce cell death through ROS mediated mitochondrial pathway
which ﬁnally ends in cytochrome c release, caspase 3 activation
and apoptosis in cancerous B-lymphocytes isolated from CLL
patients.Acknowledgment
The data provided in this article was extracted from the Ph.D.
thesis of Dr. Ahmad Salimi. The thesis was conducted under su-
pervision of Prof. Jalal Pourahmad at Department of Toxicology
and Pharmacology, Faculty of Pharmacy, Shahid Beheshti Uni-
versity of Medical Sciences, Tehran, Iran. This study was supported
by Shahid Beheshti University of Medical Sciences, Deputy of Re-
search, grant number (1392-1-132-1183).References
[1] J. Ferlay, H.R. Shin, F. Bray, et al., Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008, Int. J. Cancer 127 (12) (2010) 2893–2917.
[2] A.R. Amin, O. Kucuk, F.R. Khuri, et al., Perspectives for cancer prevention with
natural compounds, J. Clin. Oncol. 27 (16) (2009) 2712–2725.
[3] Cancer prevention with natural compounds, Seminars in Oncology, Elsevier,
2010.
[4] W.-Y. Huang, Y.-Z. Cai, Y. Zhang, Natural phenolic compounds from medicinal
herbs and dietary plants: potential use for cancer prevention, Nutr. Cancer 62
(1) (2009) 1–20.
[5] P. Ghia, A.J. Ferreri, F. Caligaris-Cappio, Chronic lymphocytic leukemia, Crit.
Rev. Oncol./Hematol. 64 (3) (2007) 234–246.
[6] C. Rozman, E. Montserrat, Chronic lymphocytic leukemia, New Engl. J. Med.
333 (16) (1995) 1052–1057.
A. Salimi et al. / Redox Biology 6 (2015) 461–471 471[7] F.L. Kiechle, X. Zhang, Apoptosis: biochemical aspects and clinical implications,
Clin. Chim. Acta 326 (1) (2002) 27–45.
[8] S. Fulda, Evasion of apoptosis as a cellular stress response in cancer, Int. J. Cell
Biol. 2010 (2010) 370835.
[9] M. Hassan, H. Watari, A. Abu Almaaty, Apoptosis and molecular targeting
therapy in cancer, BioMed Res. Int. 2014 (2014) 150845.
[10] S. Loeder, T. Zenz, A. Schnaiter, et al., A novel paradigm to trigger apoptosis in
chronic lymphocytic leukemia, Cancer Res. 69 (23) (2009) 8977–8986.
[11] S. Besbes, M. Mirshahi, M. Pocard, et al., Strategies targeting apoptosis proteins
to improve therapy of chronic lymphocytic leukemia, Blood Rev. 29 (5) (2015)
345–350.
[12] T.J. Kipps, Interview: chronic lymphocytic leukemia: treating an incurable
disease, Int. J. Hematol. Oncol. 2 (3) (2013) 203–205.
[13] M. Wu, A. Akinleye, X. Zhu, Novel agents for chronic lymphocytic leukemia, J.
Hematol. Oncol. 6 (1) (2013) 36.
[14] K. Lu, X. Wang, Therapeutic advancement of chronic lymphocytic leukemia, J.
Hematol. Oncol. 5 (1) (2012) 55.
[15] P. Vandenabeele, L. Galluzzi, T.V. Berghe, et al., Molecular mechanisms of ne-
croptosis: an ordered cellular explosion, Nat. Rev. Mol. Cell Biol. 11 (10) (2010)
700–714.
[16] R.A. Smith, R.C. Hartley, H.M. Cocheme, et al., Mitochondrial pharmacology,
Trends Pharmacol. Sci. 33 (6) (2012) 341–352.
[17] D.A. Tennant, R.V. Durán, E. Gottlieb, Targeting metabolic transformation for
cancer therapy, Nat. Rev. Cancer 10 (4) (2010) 267–277.
[18] A.F. Urra, M. Cordova-Delgado, H. Pessoa-Mahana, et al., Mitochondria: a
promising target for anticancer alkaloids, Curr. Topics Med. Chem. 13 (17)
(2013) 2171–2183.
[19] D.C. Chan, Mitochondrial fusion and ﬁssion in mammals, Annu. Rev. Cell Dev.
Biol. 22 (2006) 79–99.
[20] L.F. Yousif, K.M. Stewart, K.L. Horton, et al., Mitochondria‐penetrating pep-
tides: sequence effects and model cargo transport, ChemBioChem 10 (12)
(2009) 2081–2088.
[21] D.C. Wallace, W. Fan, V. Procaccio, Mitochondrial energetics and therapeutics,
Annu. Rev. Pathol. 5 (2010) 297.
[22] P.S. Bisen, S.S. Bundela, A. Sharma, Ellagic acid-chemopreventive role in oral
cancer, J. Cancer Sci. Ther. 4 (2012) 2.
[23] H.-M. Zhang, L. Zhao, H. Li, et al., Research progress on the anticarcinogenic
actions and mechanisms of ellagic acid, Cancer Biol. Med. 11 (2) (2014) 92.
[24] R. Rotem, A. Heyfets, O. Fingrut, et al., Jasmonates: novel anticancer agents
acting directly and selectively on human cancer cell mitochondria, Cancer Res.
65 (5) (2005) 1984–1993.
[25] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: ap-
plication to proliferation and cytotoxicity assays, J. Immunol. Methods 65 (1)
(1983) 55–63.
[26] Y. Liu, D.A. Peterson, H. Kimura, et al., Mechanism of cellular 3‐(4,5‐di-
methylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) reduction, J.
Neurochem. 69 (2) (1997) 581–593.
[27] L.-N. Qiu, Y.-L. Zhou, Z.-N. Wang, et al., ZGDHu-1 promotes apoptosis of
chronic lymphocytic leukemia cells, Int. J. Oncol. 41 (2) (2012) 533–540.
[28] E. Seydi, M. Rajabi, A. Salimi, et al., Involvement of mitochondrial mediated
caspase 3 activation and lysosomal labilization in acrylamide-induced liver
toxicity, Toxicol. Environ. Chem. 97 (5) (2015) 563–575.
[29] Adaphostin-induced apoptosis in cll b-cells is associated with induction of
oxidative stress and exhibits synergy with ﬂudarabine, ASH Annual Meeting
Abstracts, 2004.
[30] B. Kalyanaraman, V. Darley-Usmar, K.J. Davies, et al., Measuring reactive
oxygen and nitrogen species with ﬂuorescent probes: challenges and limita-
tions, Free Radic. Biol. Med. 52 (1) (2012) 1–6.
[31] K. Balakrishnan, R. Nimmanapalli, F. Ravandi, et al., Forodesine, an inhibitor ofpurine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic
leukemia cells, Blood 108 (7) (2006) 2392–2398.
[32] M. Talari, E. Seydi, A. Salimi, Dracocephalum: novel anticancer plant acting on
liver cancer cell mitochondria, BioMed Res. Int. 2014 (2014) 892170.
[33] H.J. Forman, O. Augusto, R. Brigelius-Flohe, et al., Even free radicals should
follow some rules: a guide to free radical research terminology and metho-
dology, Free Radic. Biol. Med. 78 (2015) 233–235.
[34] M. Faizi, A. Salimi, M. Rasoulzadeh, et al., Schizophrenia induces oxidative
stress and cytochrome C release in isolated rat brain mitochondria: a possible
pathway for induction of apoptosis and neurodegeneration, Iran. J. Pharm.
Res.: IJPR 13 (Suppl.) (2014) S93.
[35] A. Ferrajoli, B.-N. Lee, E.J. Schlette, et al., Lenalidomide induces complete and
partial remissions in patients with relapsed and refractory chronic lympho-
cytic leukemia, Blood 111 (11) (2008) 5291–5297.
[36] J.R. Brown, The treatment of relapsed refractory chronic lymphocytic leuke-
mia, Hematology Am. Soc. Hematol. Educ. Program 2011 (1) (2011) 110–118.
[37] H.E. Eve, D. Linch, W. Qian, et al., Toxicity of ﬂudarabine and cyclopho-
sphamide with or without rituximab as initial therapy for patients with pre-
viously untreated mantle cell lymphoma: results of a randomised phase II
study, Leuk. lymphoma 50 (2) (2009) 211–215.
[38] G. Packham, F.K. Stevenson, Bodyguards and assassins: Bcl‐2 family proteins
and apoptosis control in chronic lymphocytic leukaemia, Immunology 114 (4)
(2005) 441–449.
[39] M.E. Obrenovich, N.G. Nair, A. Beyaz, et al., The role of polyphenolic anti-
oxidants in health, disease, and aging, Rejuvenation Res. 13 (6) (2010)
631–643.
[40] M. Jang, L. Cai, G.O. Udeani, et al., Cancer chemopreventive activity of re-
sveratrol, a natural product derived from grapes, Science 275 (5297) (1997)
218–220.
[41] T.J. Sayers, Targeting the extrinsic apoptosis signaling pathway for cancer
therapy, Cancer Immunol. Immunother. 60 (8) (2011) 1173–1180.
[42] M. D’Archivio, C. Santangelo, B. Scazzocchio, et al., Modulatory effects of
polyphenols on apoptosis induction: relevance for cancer prevention, Int. J.
Mol. Sci. 9 (3) (2008) 213–228.
[43] A. Kumar, M. Chang, L. Fliegel, et al., Oxidative repression of NHE1 gene ex-
pression involves iron-mediated caspase activity, Cell Death Differ. 14 (10)
(2007) 1733–1746.
[44] P. Costantini, A.-S. Belzacq, H.L. Vieira, et al., Oxidation of a critical thiol re-
sidue of the adenine nucleotide translocator enforces Bcl-2-independent
permeability transition pore opening and apoptosis, Oncogene 19 (2) (2000)
307–314.
[45] D.F. Stowe, A.K. Camara, Mitochondrial reactive oxygen species production in
excitable cells: modulators of mitochondrial and cell function, Antioxid. Redox
Signal. 11 (6) (2009) 1373–1414.
[46] I.A. Barbosa, N.G. Machado, A.J. Skildum, et al., Mitochondrial remodeling in
cancer metabolism and survival: potential for new therapies, Biochim. Bio-
phys. Acta (BBA) – Rev. Cancer 1826 (1) (2012) 238–254.
[47] D.R. Green, G. Kroemer, The pathophysiology of mitochondrial cell death,
Science 305 (5684) (2004) 626–629.
[48] D.R. Green, G. Kroemer, Pharmacological manipulation of cell death: clinical
applications in sight? J. Clin. Investig. 115 (10) (2005) 2610.
[49] C. Brenner, S. Grimm, The permeability transition pore complex in cancer cell
death, Oncogene 25 (34) (2006) 4744–4756.
[50] A.-S. Belzacq, H.L. Vieira, F. Verrier, et al., Bcl-2 and Bax modulate adenine
nucleotide translocase activity, Cancer Res. 63 (2) (2003) 541–546.
[51] S. Desagher, A. Osen-Sand, S. Montessuit, et al., Phosphorylation of bid by
casein kinases I and II regulates its cleavage by caspase 8, Mol. Cell 8 (3) (2001)
601–611.
